PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years

NCT ID: NCT01296178

Last Updated: 2021-03-23

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-12-31
• Study Completion Date: 2021-12-31

Brief Summary

Advances in the biological characterization of AML can now make a proper estimate of the risk of recurrence and likelihood of survival of different groups of patients according to the expression of different disease parameters. Karyotype, the molecular alterations affecting genes FLT3, NPM1 and CEBPA, minimal residual disease by flow cytometry and response to first induction cycle are variables that must be taken into consideration when planning the treatment of first line from a patient with AML.

This breakthrough in the field of biology has not resulted yet in the development of new drugs really effective in the treatment of AML. Therefore, the core of the treatment continue to rely on the use of traditional chemotherapy combined or not with allogeneic hematopoietic stem cell. Both treatments differ in their antileukemic efficacy, higher in aloTPH, as well as their toxicity and procedure-related mortality, increased also in the aloTPH. These aspects should be added that most candidates aloTPH patients lack an HLA identical sibling donor forcing the search for alternative sources and hematopoietic stem cell donors. These transplants alternative, but are not committed to their antileukemic efficacy, it does have implied a greater toxicity. Therefore, the ultimate effectiveness of these procedures depends largely on the proper selection of candidates for the same.

While there is broad agreement in terms of induction chemotherapy using a combination of cytarabine with anthracycline, the choice of chemotherapy regimen is controversial postremisión today. In the poor prognosis of itself involve the LMA, patients classified as "favorable group" are acceptable disease-free survival with consolidation schemes involving high-dose cytarabine. For other patients appear to be inappropriate to combine cytarabine with an anthracycline, at least one cycle of consolidation, and raise the option of allogeneic different depending on prognostic markers

Detailed Description

Primary objectives

1. Optimizing current treatment of AML based on the classification of patients into different risk groups according to parameters cytogenetic and molecular response to treatment and to analyze its effectiveness in terms of survival.

2. Apply a uniform treatment to individual patients according to previously defined prognostic groups.

Secondary Objectives

1. Correlate the different clinical and biological characteristics with response rates and patient outcomes.

2. Studying the role of minimal residual disease by molecular techniques in anticipation of relapse of AML

Conditions

Acute Myeloblastic Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

IDARUBICINE

Administration of chemotherapy induction

Idarubicin IV Dose of 12 mg/m2/day days 1 to 3

Intervention Type: DRUG

ARA-C

ARA-C 200 mg/m2/day dose continuous infusion of IV days 1 to 7

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis of AML according to WHO criteria
• Previously untreated AML, including AML de novo,AML secondary to MDS or previous chemotherapy or radiotherapy
• No promyelocytic leukemia (no t (15, 17) or PML-RARa rearrangement and its variants)
• Age ≤ 65 years
• ECOG performance status 0-2
• Provide written informed consent
• Being able to comply with protocol procedures
• Not to be fertile or willing to use a method of birth control during treatment and until the end of it
• Adequate renal and hepatic function as follows, provided the changes, which would be not due to the disease: Total bilirubin < 1.5 x upper limit of normal (ULN) institutional and AST and ALT < 2.5 x ULN, and Serum creatinine < 2.5 mg / dL.
• Adequate cardiac function determined by at least 1 of the following:

Left ventricular ejection fraction (LVEF) > 40% measured by echocardiography in multiport scanner acquisition (MUGA) or isotope angiography, or Left ventricular fractional shortening > 22% measured in echocardiography

Exclusion Criteria

• LPA diagnosis according to WHO criteria
• Previously untreated AML, except for the administration of hydroxyurea as a cytoreductive agent which itself is permitted
• AML secondary to chronic myeloproliferative syndrome
• Age> 65 years
• ECOG performance status> 2
• Absence of written informed consent
• Being unable to comply with protocol procedures
• Be fertile and not willing to use a method of birth control during treatment and until the end of it
• Hypersensitivity to any drug protocol
• Positive for HIV
• Abnormal liver and renal functions as indicated below, provided the changes, which would be not due to the disease: Total bilirubin> 1.5 x upper limit of normal (ULN) institutional and AST and ALT> 2.5 x ULN, and serum creatinine> 2.5 mg / dL
• Altered cardiac function determined by at least 1 of the following:

Left ventricular ejection fraction (LVEF) <40% measured by echocardiography in multiport scanner acquisition (MUGA) or isotope angiography, or Left ventricular fractional shortening <22% measured by echocardiography

• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

PETHEMA Foundation

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hospital La Fe

Valencia, , Spain

Site Status: RECRUITING

Countries

Spain

Central Contacts

Federico Moscardó, Dr

Role: CONTACT

fedemoscardo@yahoo.es

+34 963862745

Facility Contacts

Federico Moscardó, Dr

Role: primary

fedemoscardo@yahoo.es

Other Identifiers

PETHEMA-LMA10

Identifier Type: -

Identifier Source: org_study_id